valproic acid has been researched along with Hyperinsulinism in 16 studies
Valproic Acid: A fatty acid with anticonvulsant and anti-manic properties that is used in the treatment of EPILEPSY and BIPOLAR DISORDER. The mechanisms of its therapeutic actions are not well understood. It may act by increasing GAMMA-AMINOBUTYRIC ACID levels in the brain or by altering the properties of VOLTAGE-GATED SODIUM CHANNELS.
valproic acid : A branched-chain saturated fatty acid that comprises of a propyl substituent on a pentanoic acid stem.
Hyperinsulinism: A syndrome with excessively high INSULIN levels in the BLOOD. It may cause HYPOGLYCEMIA. Etiology of hyperinsulinism varies, including hypersecretion of a beta cell tumor (INSULINOMA); autoantibodies against insulin (INSULIN ANTIBODIES); defective insulin receptor (INSULIN RESISTANCE); or overuse of exogenous insulin or HYPOGLYCEMIC AGENTS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We evaluated the serum leptin and insulin as predictors of weight gain in children receiving long-term treatment with valproate (VPA), carbamazepine (CBZ), lamotrigine (LTG)." | 7.75 | States of serum leptin and insulin in children with epilepsy: risk predictors of weight gain. ( Fida, NM; Hamed, EA; Hamed, SA, 2009) |
| "Body mass index (BMI) and fasting serum concentrations of insulin and lipids were measured in 102 men with epilepsy who were treated with VPA, carbamazepine (CBZ), or oxcarbazepine (OXC) monotherapy." | 5.10 | Fasting serum insulin and lipid levels in men with epilepsy. ( Isojärvi, JI; Knip, M; Kotila, M; Myllylä, VV; Pakarinen, AJ; Pylvänen, V; Rättyä, J; Turkka, J, 2003) |
| " VPA-induced weight gain seems to be associated with many metabolic disturbances; the most frequent are hyperinsulinemia and insulin resistance, hyperleptinemia and leptin resistance." | 4.89 | Metabolic and endocrine effects of valproic acid chronic treatment. ( Belcastro, V; D'Egidio, C; Striano, P; Verrotti, A, 2013) |
| "Our study was carried out to ascertain the role of valproic acid for inducing metabolic disorders like hyperinsulinemia, insulin resistance and metabolic syndrome." | 3.77 | Fasting insulin and HOMA-index changes in patients treated with valproic acid. ( Javashvili, L; Kasradze, S; Mania, M; Okujava, N, 2011) |
| "We evaluated the serum leptin and insulin as predictors of weight gain in children receiving long-term treatment with valproate (VPA), carbamazepine (CBZ), lamotrigine (LTG)." | 3.75 | States of serum leptin and insulin in children with epilepsy: risk predictors of weight gain. ( Fida, NM; Hamed, EA; Hamed, SA, 2009) |
| "Valproic acid (VPA) is effective for the treatment of many types of epilepsy, but its use can be associated with an increase in body weight." | 3.75 | Nonalcoholic fatty liver disease during valproate therapy. ( Chiarelli, F; Di Marco, G; la Torre, R; Pelliccia, P; Verrotti, A, 2009) |
| " Anthropometric measurements, staging of pubertal maturation, and clinical manifestations of hyperandrogenism were assessed, as well as measurement of serum levels of testosterone, dehydroepiandrosterone sulfate (DHEAS), sex hormone-binding globulin (SHBG), and free androgen index (FAI)." | 3.72 | Physical growth and endocrinal disorders during pubertal maturation in girls with epilepsy. ( Abd El-Basset, FZ; El Barbary, NS; El-Khayat, HA; Hakky, SM; Mohamed, MS; Nassef, NM; Tohamy, SM; Tomoum, HY; Zaky, AA, 2004) |
| "Weight gain is a known side effect of valproate (VPA) therapy, which is associated with hyperinsulinemia and polycystic ovary-like syndrome and unfavorable lipid changes in women." | 1.33 | Insulin-related metabolic changes during treatment with valproate in patients with epilepsy. ( Isojärvi, J; Knip, M; Pakarinen, A; Pylvänen, V, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (18.75) | 18.2507 |
| 2000's | 9 (56.25) | 29.6817 |
| 2010's | 4 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Belcastro, V | 1 |
| D'Egidio, C | 1 |
| Striano, P | 1 |
| Verrotti, A | 2 |
| Walker, V | 1 |
| Hamed, SA | 1 |
| Fida, NM | 1 |
| Hamed, EA | 1 |
| Di Marco, G | 1 |
| la Torre, R | 1 |
| Pelliccia, P | 1 |
| Chiarelli, F | 1 |
| Mania, M | 1 |
| Javashvili, L | 1 |
| Kasradze, S | 1 |
| Okujava, N | 1 |
| Kanemura, H | 1 |
| Sano, F | 1 |
| Maeda, Y | 1 |
| Sugita, K | 1 |
| Aihara, M | 1 |
| Pylvänen, V | 3 |
| Knip, M | 5 |
| Pakarinen, AJ | 3 |
| Turkka, J | 1 |
| Kotila, M | 1 |
| Rättyä, J | 2 |
| Myllylä, VV | 3 |
| Isojärvi, JI | 3 |
| El-Khayat, HA | 1 |
| Abd El-Basset, FZ | 1 |
| Tomoum, HY | 1 |
| Tohamy, SM | 1 |
| Zaky, AA | 1 |
| Mohamed, MS | 1 |
| Hakky, SM | 1 |
| El Barbary, NS | 1 |
| Nassef, NM | 1 |
| Pakarinen, A | 2 |
| Isojärvi, J | 3 |
| Laatikainen, TJ | 1 |
| Juntunen, KT | 1 |
| Koivunen, R | 1 |
| Tekay, A | 1 |
| Tapanainen, JS | 1 |
| Genton, P | 1 |
| Bauer, J | 1 |
| Duncan, S | 1 |
| Taylor, AE | 1 |
| Balen, AH | 1 |
| Eberle, A | 1 |
| Pedersen, B | 1 |
| Salas-Puig, X | 1 |
| Sauer, MV | 1 |
| Stephen, LJ | 1 |
| Kwan, P | 1 |
| Shapiro, D | 1 |
| Dominiczak, M | 1 |
| Brodie, MJ | 1 |
| Luef, G | 1 |
| Abraham, I | 1 |
| Trinka, E | 1 |
| Alge, A | 1 |
| Windisch, J | 1 |
| Daxenbichler, G | 1 |
| Unterberger, I | 1 |
| Seppi, K | 1 |
| Lechleitner, M | 1 |
| Krämer, G | 1 |
| Bauer, G | 1 |
3 reviews available for valproic acid and Hyperinsulinism
| Article | Year |
|---|---|
Metabolic and endocrine effects of valproic acid chronic treatment.
Topics: Anticonvulsants; Epilepsy; Humans; Hyperinsulinism; Insulin Resistance; Leptin; Metabolic Syndrome; | 2013 |
Ammonia metabolism and hyperammonemic disorders.
Topics: Ammonia; Animals; Arginine; Biological Transport; Brain; Cell Membrane; Humans; Hyperammonemia; Hype | 2014 |
On the association between valproate and polycystic ovary syndrome.
Topics: Adolescent; Adult; Anticonvulsants; Comorbidity; Epilepsy; Female; Humans; Hyperinsulinism; Insulin | 2001 |
2 trials available for valproic acid and Hyperinsulinism
| Article | Year |
|---|---|
Valproate sodium enhances body weight gain in patients with childhood epilepsy: a pathogenic mechanisms and open-label clinical trial of behavior therapy.
Topics: Adolescent; Anticonvulsants; Behavior Therapy; Body Mass Index; Child; Epilepsy; Female; Humans; Hyp | 2012 |
Fasting serum insulin and lipid levels in men with epilepsy.
Topics: Adolescent; Adult; Anticonvulsants; Body Mass Index; Carbamazepine; Epilepsy; Fasting; Humans; Hyper | 2003 |
11 other studies available for valproic acid and Hyperinsulinism
| Article | Year |
|---|---|
States of serum leptin and insulin in children with epilepsy: risk predictors of weight gain.
Topics: Adolescent; Age Factors; Anticonvulsants; Body Mass Index; Carbamazepine; Case-Control Studies; Chil | 2009 |
Nonalcoholic fatty liver disease during valproate therapy.
Topics: Anticonvulsants; Body Mass Index; Child; Epilepsy; Fatty Liver; Fatty Liver, Alcoholic; Female; Huma | 2009 |
Fasting insulin and HOMA-index changes in patients treated with valproic acid.
Topics: Adult; Blood Glucose; Body Mass Index; C-Peptide; Carbamazepine; Cholesterol, HDL; Epilepsy; Female; | 2011 |
Physical growth and endocrinal disorders during pubertal maturation in girls with epilepsy.
Topics: Adolescent; Anticonvulsants; Carbamazepine; Child; Dehydroepiandrosterone; Epilepsy; Female; Growth; | 2004 |
Insulin-related metabolic changes during treatment with valproate in patients with epilepsy.
Topics: Adult; Anticonvulsants; Body Mass Index; Epilepsy; Female; Humans; Hyperinsulinism; Insulin; Lipopro | 2006 |
Characterization of insulin secretion in Valproate-treated patients with epilepsy.
Topics: Adult; Anticonvulsants; Blood Glucose; C-Peptide; Epilepsy; Fasting; Female; Humans; Hyperinsulinism | 2006 |
Obesity and endocrine disorders in women taking valproate for epilepsy.
Topics: Adult; Body Weight; Carbamazepine; Dehydroepiandrosterone; Dehydroepiandrosterone Sulfate; Endocrine | 1996 |
Valproate, lamotrigine, and insulin-mediated risks in women with epilepsy.
Topics: Analysis of Variance; Anticonvulsants; Cholesterol, HDL; Epilepsy; Female; Follow-Up Studies; Humans | 1998 |
[The dangers of valproate in women].
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Cholesterol, HDL; Epilepsy; Female; Humans; Hyperandro | 1998 |
Hormone profiles in young adults with epilepsy treated with sodium valproate or lamotrigine monotherapy.
Topics: Adult; Anticonvulsants; Blood Glucose; Body Mass Index; Comorbidity; Dehydroepiandrosterone; Epileps | 2001 |
Hyperandrogenism, postprandial hyperinsulinism and the risk of PCOS in a cross sectional study of women with epilepsy treated with valproate.
Topics: Adult; Anticonvulsants; Body Mass Index; Body Weight; Confidence Intervals; Cross-Sectional Studies; | 2002 |